Screening for Factor V Leiden Mutation (FVL)in Users of Combined Oral Contraceptives (COC)or Hormone Replacement Therapy (HRT)


Authors: D. Cibula 1;  V. Unzeitig 2;  J. Živný 1
Authors‘ workplace: Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, přednosta prof. MUDr. J. Živný, DrSc. 2Gynekologicko-porodnická klinika, LF MU a FN Brno, přednosta prof. MUDr. P. Ventruba, DrSc. 1
Published in: Čes. Gynek.2003, , č. 3 s. 167-174
Category:

Overview

Objective:
Analysis of the issue of screening for Factor V Leiden mutation (FVL) in users of combinedoral contraceptives (COC) or hormone replacement therapy (HRT).Design: Review article.Setting: Department of Obstetrics and Gynecology, Charles University and GeneralFaculty Hospital,Prague.Methods: Review of published facts, analysis of possibilities to screen all users or to test risk groupsin the current situation in the Czech Republic.Conclusion: 1) Screening for FVL in allCOCorHRTusers is not recommended mostly for economicalreasons. 2) Testing for FVL is indicated in women with a positive family history of thromboembolicdisease and in obese women, if they consider COC or HRT despite our recommendation or in casethere is a medical indication. 3) Deep venous thrombosis or pulmonary embolism are absolutecontraindications of COC or HRT regardless of the presence of FVL.

Key words:
combined oral contraceptives, hormone replacement therapy, thromboembolic disease,Factor V Leiden mutation, hereditary thrombophilias

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine

Article was published in

Czech Gynaecology


2003 Issue 3

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account